Berna Vax Biotech AGWe are a key player in the modern VACCINE world
"Health through Prevention"
Shaping the future of Health by being an important pillar of communicable disease prevention so that every child and every person in the world has access to vaccines.
Vision
Be an important pillar of communicable disease prevention so that every child and every person in the world has access to vaccines
Solve Vaccine Shortages
Address global vaccine supply challenges
Faster Response
React quickly to new epidemics and pandemics
Life-Saving Impact
Increase vaccine impact worldwide
Disease Eradication
Integral element in viral disease elimination
Operational Business
Reviving Swiss Production
Reviving vaccines production against Measles, Mumps, Rubella, Varicella and Hepatitis B in Switzerland
New Market Vaccines
Bring new vaccines to the market according to our pipeline
Global Sales Network
Establish the sales of Human Attenuated Viral Vaccines, world-wide
Global Accessibility
Make our novel products accessible world-wide
Research & Development
Target cancer, transmissible and chronic diseases with the overall goal to develop and produce life-saving and life-enhancing therapeutics and vaccines
Vectored Vaccines
Reverse Genetics
Live attenuated measles virus (MV) vaccines have an impressive record of safety, efficacy and ability to induce life-long immunity against infection. Using reverse genetics technology, such negative strand RNA viruses can be rescued from cloned DNA.
This technology allows the insertion of exogenous genes encoding foreign antigens or even monoclonal antibodies into BernaVax MV genome in such the way that it can be expressed by the MV strain.
Late Phase Pipeline
Early Phase Pipeline
One Health Concept
BernaVax is committed to the "One Health Concept", as we believe that Zoonosis can only be avoided if animals are healthy. Veterinary vaccines are, therefore, part of our mission.
Veterinary Vaccines - First Priority:
Oncology
With our existing technologies and platforms, we are at the forefront to develop methods to cope with cancer treatment.
We plan to use "reverse genetics of live attenuated measles virus vaccine" to develop an antitumoral vaccine. Our approach is based on successful clinical trials.
The FUTURE is based on the EXPERIENCE of Our Team
Core Team
Leadership Excellence
Long standing experience in management position within international renowned companies in research, development and production of a wide range of vaccines and a track record in the construction of vaccine facilities.
Scientists
Research Expertise
Extensive experience in the field of vaccines production, R&D, Quality Control and Quality Assurance, or previously held senior position in biotechnology, IT and engineering.
Investors
Join us in revolutionizing global health through innovative vaccine solutions
Investment Opportunity
BernaVax represents a unique investment opportunity in the rapidly growing global vaccine market. With our innovative technology platforms and extensive pipeline, we are positioned to address critical unmet medical needs while generating significant returns.
Experienced Leadership
Led by industry veterans with proven track records in vaccine development and commercialization
Innovative Technology
Proprietary reverse genetics platform with measles virus vector technology
Diversified Portfolio
Human vaccines, veterinary vaccines, and oncology therapeutics across multiple indications
Ready to Invest in the Future of Health?
Join us in our mission to make life-saving vaccines accessible worldwide while generating exceptional returns for our investors.
Contact Us
Get in touch to learn more about our vaccine solutions
info@bernavax.com
Phone
+41 78 685 82 58
Location
Grafenaustrasse 11, 6300 Zug , Switzerland
